French field experience with buprenorphine

被引:175
|
作者
Auriacombe, M
Fatséas, M
Dubernet, J
Daulouède, JP
Tignol, J
机构
[1] Univ Bordeaux 2, Victor Pachon Med Sch, Dept Psychiat & Addict, F-33076 Bordeaux, France
[2] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA
来源
关键词
D O I
10.1080/10550490490440780
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
In most European countries, methadone treatment is provided to 20-30% of opiate abusers who need treatment due to regulations and concerns about safety. To address this need in France, all registered medical doctors since 1995 have been allowed to prescribe buprenorphine (BUP) without any special education or licensing. This led to treating approximately 65,000 patients per year with BUP, about ten times more than with more restrictive methadone policies. French physician compensation mechanisms, pharmacy services, and medical insurance funding all minimized barriers to BUP BUP treatment. About 20% of all physicians in France are using BUP to treat about half of the estimated 150,000 problem heroin users. Daily supervised dosing by a phamacist for the first six months resulted in significantly better treatment retention (80% vs 46%) and lower heroin use. Intravenous diversion of BUP may occur in up to 20% of BUP patients and has led to various infections and relatively rare overdoses in combination with sedatives. Opiate overdose deaths have declined substantially (by 79%) since BUP was introduced in 1995. Newborn opiate withdrawal in mothers treated with buprenorphine compared to methadone was reported to be less frequent, less severe, and of shorter duration. Although some of the public health benefits seen during the time of buprenorphine expansion in France might be contigent upon characteristics of the French health and social services system, the French model raises questions about the value of tight regulations on prescribing BUP imposed by many countries throughout the world.
引用
收藏
页码:S17 / S28
页数:12
相关论文
共 50 条
  • [1] French Experience with Buprenorphine : Do Physicians Follow the Guidelines?
    Landreat, Morgane Guillou
    Rozaire, Charles
    Guillet, Jean Yves
    Vigneau, Caroline Victorri
    Le Reste, Jean Yves
    Bronnec, Marie Grall
    [J]. PLOS ONE, 2015, 10 (10):
  • [2] Use of buprenorphine for substitution treatment: A French experience in Bordeaux and Bayonne
    Auriacombe, M
    Franques, P
    Bertorelle, V
    Tignol, J
    [J]. BUPRENORPHINE - A SUBSTITUTION AGENT FOR THE TREATMENT OF OPIOID ADDICTION: A UK PERSPECTIVE, 1997, 19 (02): : 47 - 50
  • [3] Opioid maintenance treatment with buprenorphine: the French experience, 1996-2010
    Baumevieille, M.
    Mallaret, M.
    Daveluy, A.
    Haramburu, F.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 77 - 77
  • [4] Buprenorphine use: The international experience
    Carrieri, Maria Patrizia
    Amass, Leslie
    Lucas, Gregory M.
    Vlahov, David
    Wodak, Alex
    Woody, George E.
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 : S197 - S215
  • [5] Buprenorphine exposures in adolescents and adults: a 10-year experience of a French Poison Control Center
    Boulamery, Audrey
    von Fabeck, Katharina
    Glaizal, Mathieu
    de Haro, Luc
    Simon, Nicolas
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 (04) : 764 - 770
  • [6] What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine
    Vorspan, Florence
    Hjelmstrom, Peter
    Simon, Nicolas
    Benyamina, Amine
    Dervaux, Alain
    Brousse, Georges
    Jamain, Thierry
    Kosim, Margaux
    Rolland, Benjamin
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2019, 16 (09) : 907 - 914
  • [7] Review one year after a switch buprenorphine to buprenorphine/naloxone in a French prison
    Prigent, Anais
    Taurin, Stephane
    Tiret, Isabelle
    Varin, Remi
    Dieu, Bernard
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 316 - 317
  • [8] CLINICAL-EXPERIENCE WITH THE ANALGESIC BUPRENORPHINE
    JACOBS, CH
    FARRIS, HE
    [J]. LABORATORY ANIMAL SCIENCE, 1987, 37 (04): : 521 - 521
  • [9] Singapore's Experience With Buprenorphine (Subutex)
    Noroozi, Alireza
    Mianji, Fahimeh
    [J]. IRANIAN JOURNAL OF PSYCHIATRY AND BEHAVIORAL SCIENCES, 2008, 2 (01) : 54 - 59
  • [10] Initial experience with buprenorphine in primary care
    Dougherty, RJ
    [J]. JOURNAL OF ADDICTIVE DISEASES, 2004, 23 (02) : 132 - 132